Ultragenyx Pharma (RARE) Announces Statistically Significant Data from Triheptanoin Glut1 DS Study
Tweet Send to a Friend
Ultragenyx Pharma (NASDAQ: RARE) announced the presentation of positive data from an investigator-sponsored trial of triheptanoin (UX007) for the treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE